Existing evidence has shown that RIOK2 is involved in non-small cell lung cancer, glioblastoma, hepatocellular carcinoma, acute myeloid leukemia, and prostate cancer progression. This evidence concerns the gene RIOK2 and hepatocellular carcinoma.